Tailoring pharmacotherapy for male lower urinary tract symptoms: A prospective, multicenter, observational trial

The aim of this study was to evaluate the pattern of tailoring and efficacy of several types of pharmacotherapy in male LUTS.

[1]  J. Weiss,et al.  Nocturia: aetiology and treatment in adults , 2016, Nature Reviews Urology.

[2]  N. Longo,et al.  α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. , 2016, European urology.

[3]  Hoon Choi,et al.  Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South Korea , 2016, International neurourology journal.

[4]  Jin Wook Kim,et al.  Nocturia: The circadian voiding disorder , 2016, Investigative and clinical urology.

[5]  S. Gravas,et al.  New therapeutic strategies for the treatment of male lower urinary tract symptoms. , 2016 .

[6]  J. Kim,et al.  Korean clinical practice guideline for benign prostatic hyperplasia , 2016, Investigative and clinical urology.

[7]  Tae Heon Kim,et al.  The Impact of Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Depressive Symptoms, and Sexuality in Korean Men Aged 40 Years and Older: A Population-Based Survey , 2015, International neurourology journal.

[8]  R. Kirby,et al.  Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK , 2015, BJU international.

[9]  M. Miner,et al.  A practical primary care approach to lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH-LUTS). , 2014, The Canadian journal of urology.

[10]  Alexander Bachmann,et al.  EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. , 2013, European urology.

[11]  S. Jinza,et al.  [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. , 2012, Hinyokika kiyo. Acta urologica Japonica.

[12]  Seung-June Oh,et al.  Short‐term effects of systematized behavioral modification program for nocturia: A prospective study , 2012, Neurourology and urodynamics.

[13]  R. Kirby,et al.  BENIGN PROSTATIC HYPERPLASIA: COUNTING THE COST OF ITS MANAGEMENT , 2010, BJU international.

[14]  T. Wilt,et al.  Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. , 2009, The Cochrane database of systematic reviews.

[15]  C. Roehrborn,et al.  Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms , 2009, BJU international.

[16]  C. Roehrborn,et al.  Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies , 2008, BJU international.

[17]  N. Théret,et al.  Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries , 2008, BJU international.

[18]  S. Kaplan,et al.  A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting , 2007, International journal of clinical practice.

[19]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[20]  C. Kelleher,et al.  The current and future burden and cost of overactive bladder in five European countries. , 2006, European urology.

[21]  H. Jeong,et al.  Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. , 2005, The Journal of urology.

[22]  P. Boyle,et al.  [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)]. , 2003, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[23]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[24]  C. Alamanis,et al.  Symptomatic benign prostate hyperplasia: impact on partners' quality of life. , 2002, European urology.

[25]  Poul Jennum,et al.  The standardisation of terminology in nocturia: Report from the standardisation sub‐committee of the International Continence Society , 2002, Neurourology and urodynamics.

[26]  M. Barry,et al.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. , 2002, Urology.

[27]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[28]  M. Oelke,et al.  Male Lower Urinary Tract Symptoms (MLUTS) , 2016 .

[29]  Eter,et al.  THE EFFECT OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND THE NEED FOR SURGICAL TREATMENT AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA , 2000 .